Results 61 to 70 of about 166,355 (310)

Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin- induced cytotoxicity [PDF]

, 2014
BACKGROUND: Antiprogestin compounds have been shown to be effective in blocking the growth of ovarian cancer cells of different genetic backgrounds.
Gamarra Luques, Carlos Diego, Goyeneche, Alicia, Hapon, María Belén, Telleria, Carlos Marcelo   +3 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance [PDF]

ChemMedChem, 2014
AbstractCyclooxygenase (COX) is an enzyme involved in tumorigenesis and is associated with tumor cell resistance against platinum‐based antitumor drugs. Cisplatin analogues were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously observed in combination treatments.
Wilma, Neumann, Brenda C, Crews, Menyhárt B, Sárosi, Cristina M, Daniel, Kebreab, Ghebreselasie, Matthias S, Scholz, Lawrence J, Marnett, Evamarie, Hey-Hawkins   +7 more
openaire   +2 more sources

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer

Cell Death Discovery
Cisplatin is a first-line drug for the treatment of small cell lung cancer (SCLC). Although the majority of patients with SCLC initially respond to cisplatin therapy, cisplatin resistance readily develops, leading to tumor progression.
Jiayi Xie, Huiying Liu, Chunqian Yang, Weitao Shen, Jian Zhang   +4 more
doaj   +1 more source

Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer [PDF]

, 2016
The small GTPase Rab25 has been functionally linked to tumour progression and aggressiveness in ovarian cancer and promotes invasion in three-dimensional environments.
Chalmers, Anthony J., Gomez-Roman, Natividad, McGregor, Fiona, Plumb, Jane   +3 more
core   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer

Chinese Journal of Lung Cancer, 2023
As one of the most common malignant tumors, lung cancer poses a serious threat to human life and health. The platinum-based drug cisplatin (DDP) is used as the first-line treatment for lung cancer.
Jinzhe SUN, Jun CHEN
doaj   +1 more source

European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects. [PDF]

, 2019
Background: Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of patients but the underlying molecular mechanism(s) are unclear and there ...
Abedi, Sina, Atilano, Shari R, Bota, Daniela, Chang, Steven, Chwa, Marilyn, Jazwinski, S Michal, Kenney, M Cristina, Liu, Catherine, Lu, Stephanie, Miceli, Michael V, Norman, Lucas, Patel, Tej H, Thaker, Kunal, Udar, Nitin   +13 more
core   +1 more source

New trends for metal complexes with anticancer activity [PDF]

, 2008
Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is,
Ang, Ang, Barnard, Barnes, Bednarski, Bergamo, Bregman, Calderone, Casini, Debreczeni, Dixon, Dyson, Failes, Feazell, Guo, Habtemariam, Hall, Hambley, Hannon, Harris, Heringova, Hillard, Hotze, James, Jung, Komeda, Liu, Lutterman, MacDiarmid, Mackay, Mackay, McNae, Meggers, Milacic, Noor, Oleksi, Orvig, Ott, Pascu, Peacock, Peter J Sadler, Pieter CA Bruijnincx, Reed, Schatzschneider, Schlawe, Scolaro, Smalley, Sun, Thompson, Timerbaev, Urig, Urig, van Zutphen, Wang, Weidt, Yan, Yang   +56 more
core   +1 more source

MiRNAs as novel adipokines : obesity-related circulating MiRNAs influence chemosensitivity in cancer patients [PDF]

, 2020
Adipose tissue is an endocrine organ, capable of regulating distant physiological processes in other tissues via the release of adipokines into the bloodstream.
Dewhurst, T, Hammond, CJ, Topham, CH, Withers, SB   +3 more
core   +2 more sources